1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 LYS 2 - GLY 3 MODEL 1 OMEGA = 148.91 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 3 - LYS 4 MODEL 1 OMEGA = 210.78 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 25 - CYS 26 MODEL 1 OMEGA = 210.64 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 1 - LYS 2 MODEL 2 OMEGA = 210.60 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 2 OMEGA = 210.11 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 16 - SER 17 MODEL 2 OMEGA = 210.32 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 18 - SER 19 MODEL 2 OMEGA = 210.06 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 4 - GLY 5 MODEL 3 OMEGA = 210.33 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 3 OMEGA = 210.47 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION MET 12 - TYR 13 MODEL 3 OMEGA = 149.80 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 16 - SER 17 MODEL 3 OMEGA = 210.90 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 18 - SER 19 MODEL 3 OMEGA = 210.74 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 2 - GLY 3 MODEL 4 OMEGA = 149.39 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 3 - LYS 4 MODEL 4 OMEGA = 210.17 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 25 - CYS 26 MODEL 4 OMEGA = 210.88 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 3 - LYS 4 MODEL 5 OMEGA = 210.46 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 5 OMEGA = 210.13 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 18 - SER 19 MODEL 5 OMEGA = 210.07 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 25 - CYS 26 MODEL 5 OMEGA = 211.17 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 2 - GLY 3 MODEL 6 OMEGA = 149.18 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 1 - LYS 2 MODEL 7 OMEGA = 210.47 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 2 - GLY 3 MODEL 7 OMEGA = 148.72 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 3 - LYS 4 MODEL 7 OMEGA = 210.60 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 7 OMEGA = 210.28 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 16 - SER 17 MODEL 7 OMEGA = 210.33 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 25 - CYS 26 MODEL 7 OMEGA = 211.16 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 2 - GLY 3 MODEL 8 OMEGA = 149.60 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 16 - SER 17 MODEL 8 OMEGA = 210.08 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 9 OMEGA = 210.31 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 16 - SER 17 MODEL 9 OMEGA = 210.41 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 1 - LYS 2 MODEL 10 OMEGA = 210.21 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 2 - GLY 3 MODEL 10 OMEGA = 148.67 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 3 - LYS 4 MODEL 10 OMEGA = 210.30 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 10 OMEGA = 210.46 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 20 - GLY 21 MODEL 10 OMEGA = 210.21 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 25 - CYS 26 MODEL 10 OMEGA = 210.35 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 2 - GLY 3 MODEL 11 OMEGA = 149.99 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION SER 17 - GLY 18 MODEL 11 OMEGA = 210.04 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 12 OMEGA = 210.13 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 25 - CYS 26 MODEL 12 OMEGA = 211.32 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 2 - GLY 3 MODEL 13 OMEGA = 149.83 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION GLY 3 - LYS 4 MODEL 13 OMEGA = 210.39 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 13 OMEGA = 210.20 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION LYS 25 - CYS 26 MODEL 13 OMEGA = 210.60 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ARG 9 - LYS 10 MODEL 14 OMEGA = 210.52 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION ASP 14 - CYS 15 MODEL 14 OMEGA = 210.33 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION CYS 16 - SER 17 MODEL 15 OMEGA = 210.45 PEPTIDE BOND DEVIATES SIGNIFICANTLY FROM TRANS CONFORMATION Farr-Jones, S. Basus, V.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking H2 N 16.023 AMINO GROUP non-polymer C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking UK J.Mol.Biol. JMOBAK 0070 0022-2836 248 106 124 10.1006/jmbi.1995.0205 7731037 Solution structure of omega-conotoxin MVIIC, a high affinity ligand of P-type calcium channels, using 1H NMR spectroscopy and complete relaxation matrix analysis. 1995 US Neuron NERNET 2038 0896-6273 9 69 A New Conus Peptide Ligand for Mammalian Presynaptic Ca2+ Channels 1992 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 2761.348 OMEGA-CONOTOXIN M VII C (M SEVEN C) 1 nat polymer SNX-230 no yes CKGKGAPCRKTMYDCCSGSCGRRGKC(NH2) CKGKGAPCRKTMYDCCSGSCGRRGKCX A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n magus cone Conus sample 6492 VENOM DUCT Conus magus pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list struct_conf struct_conf_type repository Initial release Version format compliance Version format compliance Derived calculations Other 1 0 1995-12-01 1 1 2008-03-24 1 2 2011-07-13 1 3 2017-11-29 _pdbx_database_status.process_site Y BNL 1994-12-20 REL REL 15 PEARLMAN,CASE,CALDWELL,SEIBEL,SINGH,WEINER,KOLLMAN refinement AMBER 4.1 CYS 1 n 1 CYS 1 A LYS 2 n 2 LYS 2 A GLY 3 n 3 GLY 3 A LYS 4 n 4 LYS 4 A GLY 5 n 5 GLY 5 A ALA 6 n 6 ALA 6 A PRO 7 n 7 PRO 7 A CYS 8 n 8 CYS 8 A ARG 9 n 9 ARG 9 A LYS 10 n 10 LYS 10 A THR 11 n 11 THR 11 A MET 12 n 12 MET 12 A TYR 13 n 13 TYR 13 A ASP 14 n 14 ASP 14 A CYS 15 n 15 CYS 15 A CYS 16 n 16 CYS 16 A SER 17 n 17 SER 17 A GLY 18 n 18 GLY 18 A SER 19 n 19 SER 19 A CYS 20 n 20 CYS 20 A GLY 21 n 21 GLY 21 A ARG 22 n 22 ARG 22 A ARG 23 n 23 ARG 23 A GLY 24 n 24 GLY 24 A LYS 25 n 25 LYS 25 A CYS 26 n 26 CYS 26 A NH2 27 n 27 NH2 27 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 1 A A LYS GLY 2 3 148.91 1 A A GLY LYS 3 4 -149.22 1 A A LYS CYS 25 26 -149.36 2 A A CYS LYS 1 2 -149.40 2 A A ARG LYS 9 10 -149.89 2 A A CYS SER 16 17 -149.68 2 A A GLY SER 18 19 -149.94 3 A A LYS GLY 4 5 -149.67 3 A A ARG LYS 9 10 -149.53 3 A A MET TYR 12 13 149.80 3 A A CYS SER 16 17 -149.10 3 A A GLY SER 18 19 -149.26 4 A A LYS GLY 2 3 149.39 4 A A GLY LYS 3 4 -149.83 4 A A LYS CYS 25 26 -149.12 5 A A GLY LYS 3 4 -149.54 5 A A ARG LYS 9 10 -149.87 5 A A GLY SER 18 19 -149.93 5 A A LYS CYS 25 26 -148.83 6 A A LYS GLY 2 3 149.18 7 A A CYS LYS 1 2 -149.53 7 A A LYS GLY 2 3 148.72 7 A A GLY LYS 3 4 -149.40 7 A A ARG LYS 9 10 -149.72 7 A A CYS SER 16 17 -149.67 7 A A LYS CYS 25 26 -148.84 8 A A LYS GLY 2 3 149.60 8 A A CYS SER 16 17 -149.92 9 A A ARG LYS 9 10 -149.69 9 A A CYS SER 16 17 -149.59 10 A A CYS LYS 1 2 -149.79 10 A A LYS GLY 2 3 148.67 10 A A GLY LYS 3 4 -149.70 10 A A ARG LYS 9 10 -149.54 10 A A CYS GLY 20 21 -149.79 10 A A LYS CYS 25 26 -149.65 11 A A LYS GLY 2 3 149.99 11 A A SER GLY 17 18 -149.96 12 A A ARG LYS 9 10 -149.87 12 A A LYS CYS 25 26 -148.68 13 A A LYS GLY 2 3 149.83 13 A A GLY LYS 3 4 -149.61 13 A A ARG LYS 9 10 -149.80 13 A A LYS CYS 25 26 -149.40 14 A A ARG LYS 9 10 -149.48 14 A A ASP CYS 14 15 -149.67 15 A A CYS SER 16 17 -149.55 1 A ARG 23 0.105 SIDE CHAIN 4 A ARG 9 0.083 SIDE CHAIN 5 A ARG 9 0.122 SIDE CHAIN 5 A TYR 13 0.128 SIDE CHAIN 6 A TYR 13 0.086 SIDE CHAIN 6 A ARG 22 0.129 SIDE CHAIN 7 A ARG 9 0.102 SIDE CHAIN 8 A TYR 13 0.149 SIDE CHAIN 9 A TYR 13 0.066 SIDE CHAIN 9 A ARG 23 0.091 SIDE CHAIN 10 A TYR 13 0.163 SIDE CHAIN 11 A ARG 9 0.114 SIDE CHAIN 11 A TYR 13 0.090 SIDE CHAIN 12 A ARG 9 0.108 SIDE CHAIN 14 A ARG 9 0.145 SIDE CHAIN 15 A TYR 13 0.096 SIDE CHAIN 1 -4.27 0.60 121.00 116.73 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 2 7.76 1.20 111.50 119.26 A A A CB CA C CYS CYS CYS 1 1 1 N 2 -4.13 0.60 121.00 116.87 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 2 13.45 1.50 110.80 124.25 A A A N CA CB CYS CYS CYS 26 26 26 N 3 19.45 2.00 110.40 129.85 A A A CB CA C LYS LYS LYS 2 2 2 N 3 6.87 1.10 114.20 121.07 A A A CA CB SG CYS CYS CYS 16 16 16 N 3 10.20 1.50 110.80 121.00 A A A N CA CB CYS CYS CYS 26 26 26 N 4 -4.25 0.60 121.00 116.75 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 4 9.50 1.50 110.80 120.30 A A A N CA CB CYS CYS CYS 26 26 26 N 5 -4.09 0.60 121.00 116.91 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 6 8.61 1.20 111.50 120.11 A A A CB CA C CYS CYS CYS 1 1 1 N 6 -4.93 0.60 121.00 116.07 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 6 11.68 1.50 110.80 122.48 A A A N CA CB CYS CYS CYS 26 26 26 N 7 7.93 1.20 111.50 119.43 A A A CB CA C CYS CYS CYS 1 1 1 N 7 -4.29 0.60 121.00 116.71 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 7 10.93 1.10 114.20 125.13 A A A CA CB SG CYS CYS CYS 26 26 26 N 8 13.16 2.10 122.30 135.46 A A A C N CA LYS GLY GLY 4 5 5 Y 8 -3.08 0.50 120.30 117.22 A A A NE CZ NH2 ARG ARG ARG 9 9 9 N 8 -4.83 0.60 121.00 116.17 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 8 9.92 1.50 110.80 120.72 A A A N CA CB CYS CYS CYS 26 26 26 N 9 -3.03 0.50 120.30 117.27 A A A NE CZ NH2 ARG ARG ARG 9 9 9 N 9 -4.63 0.60 121.00 116.37 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 9 12.87 1.50 110.80 123.67 A A A N CA CB CYS CYS CYS 26 26 26 N 10 -4.77 0.60 121.00 116.23 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 10 11.57 1.50 110.80 122.37 A A A N CA CB CYS CYS CYS 26 26 26 N 11 12.99 2.10 122.30 135.29 A A A C N CA LYS GLY GLY 4 5 5 Y 11 -5.09 0.60 121.00 115.91 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 11 10.18 1.50 110.80 120.98 A A A N CA CB CYS CYS CYS 26 26 26 N 12 -4.45 0.60 121.00 116.55 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 13 -3.19 0.50 120.30 117.11 A A A NE CZ NH2 ARG ARG ARG 9 9 9 N 13 -4.30 0.60 121.00 116.70 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 14 -4.08 0.60 121.00 116.92 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 14 10.61 1.50 110.80 121.41 A A A N CA CB CYS CYS CYS 26 26 26 N 15 -4.96 0.60 121.00 116.04 A A A CB CG CD1 TYR TYR TYR 13 13 13 N 15 12.05 1.50 110.80 122.85 A A A N CA CB CYS CYS CYS 26 26 26 N 1 A LYS 2 -63.05 -169.69 1 A ARG 9 -109.72 78.19 1 A LYS 10 -29.23 -67.73 1 A SER 17 -125.09 -92.05 1 A CYS 20 -61.40 75.20 2 A MET 12 -82.60 43.46 2 A TYR 13 28.29 81.53 2 A SER 17 -159.67 -92.70 2 A CYS 20 -66.77 93.60 2 A ARG 22 78.86 -50.94 2 A ARG 23 -62.12 7.06 3 A PRO 7 -58.04 87.78 3 A MET 12 -97.76 46.88 3 A CYS 15 -81.71 36.95 3 A CYS 16 60.36 -33.30 3 A SER 17 -148.29 -107.06 3 A CYS 20 -6.66 84.28 4 A MET 12 -94.64 47.94 4 A SER 17 -109.46 -91.52 4 A CYS 20 -66.28 99.27 4 A ARG 22 -78.66 21.84 5 A ARG 9 -118.32 67.35 5 A SER 17 -123.68 -103.15 5 A CYS 20 -63.87 90.06 6 A LYS 2 -160.04 -168.56 6 A LYS 10 -88.16 42.45 6 A THR 11 -112.92 -92.37 6 A MET 12 -76.22 37.66 6 A ARG 22 -154.93 -64.47 7 A SER 17 -167.01 -90.04 7 A SER 19 -126.64 -167.19 7 A ARG 22 59.87 -106.79 8 A LYS 4 37.58 115.89 8 A PRO 7 -52.30 96.73 8 A ARG 9 -118.00 61.31 8 A MET 12 -80.10 31.42 8 A CYS 15 -78.16 21.40 8 A CYS 16 61.81 -34.62 8 A SER 17 -125.42 -97.17 8 A ARG 22 68.81 -43.81 9 A LYS 10 -40.65 -77.26 9 A MET 12 -83.28 37.58 9 A TYR 13 57.13 73.38 9 A SER 17 -167.72 -90.82 9 A ARG 22 77.82 -57.73 9 A ARG 23 -67.40 1.96 10 A LYS 10 -54.63 -70.33 10 A MET 12 -89.12 35.64 10 A TYR 13 28.98 61.47 10 A SER 17 -153.46 63.26 10 A CYS 20 -35.33 85.92 11 A LYS 10 -67.24 19.43 11 A THR 11 -99.41 -91.68 11 A MET 12 -75.71 38.99 11 A CYS 15 -68.69 7.71 11 A CYS 16 68.89 -41.70 11 A ARG 22 -123.72 -62.43 12 A LYS 10 -47.87 -76.74 12 A MET 12 -85.98 38.04 12 A TYR 13 57.82 71.11 12 A SER 17 -117.01 -103.30 12 A ARG 22 74.02 -34.88 13 A ARG 9 -115.84 66.19 13 A MET 12 -79.94 30.73 13 A SER 17 -118.02 -102.69 13 A ARG 22 -102.11 -64.62 14 A LYS 10 -36.79 -77.36 14 A MET 12 -88.90 40.58 14 A TYR 13 26.65 65.00 14 A CYS 16 63.10 -47.76 14 A SER 17 178.74 154.30 14 A ARG 22 -149.56 -102.67 14 A ARG 23 -60.57 12.05 15 A LYS 10 -77.64 30.13 15 A THR 11 -109.91 -86.23 15 A MET 12 -73.09 37.78 15 A CYS 16 68.27 -32.41 15 A SER 17 -148.49 -93.92 15 A ARG 23 -151.72 25.02 refinement AMBER OMEGA-CONOTOXIN M VII C (M SEVEN C) SOLUTION STRUCTURE OF OMEGA-CONOTOXIN MVIIC, A HIGH AFFINITY OF P-TYPE CALCIUM CHANNELS, USING 1H NMR SPECTROSCOPY AND COMPLETE RELAXATION MATRIX ANALYSIS 1 Y N A LYS 10 A LYS 10 HELX_P A MET 12 A MET 12 5 1 3 disulf 2.090 A CYS 1 A SG CYS 1 1_555 A CYS 16 A SG CYS 16 1_555 disulf 2.069 A CYS 8 A SG CYS 8 1_555 A CYS 20 A SG CYS 20 1_555 disulf 2.083 A CYS 15 A SG CYS 15 1_555 A CYS 26 A SG CYS 26 1_555 covale 1.326 A CYS 26 A C CYS 26 1_555 A NH2 27 A N NH2 27 1_555 NEUROTOXIN P-TYPE CALCIUM CHANNEL BLOCKER, CONUS VENOM, PRESYNAPTIC NEUROTOXIN, CONOTOXIN, NEUROTOXIN CXO7C_CONMA UNP 1 1 P37300 TRCKGKGAPCRKTMYDCCSGSCGRRGKCG 3 28 1OMN 1 26 P37300 A 1 1 26 3 anti-parallel anti-parallel A ALA 6 A ALA 6 A CYS 8 A CYS 8 A GLY 24 A GLY 24 A CYS 26 A CYS 26 A SER 19 A SER 19 A GLY 21 A GLY 21 BINDING SITE FOR RESIDUE NH2 A 27 Software 4 A CYS 15 A CYS 15 4 1_555 A SER 19 A SER 19 4 1_555 A LYS 25 A LYS 25 4 1_555 A CYS 26 A CYS 26 4 1_555 1 P 1